Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.




  • Lung Cancer — RET-Positive NSCLC: Treatment Options for a Rare, But Targetable, Rearrangement – BreakingMED
  • Selective RET inhibitors, such as the FDA-approved selpercatinib and pralsetinib, have offered singular results in the treatment of RET-positive non-small cell lung cancer, according to a review of clinical trials of the drug class.
    V. Abramson, MD
  • Psoriasis — Clinical Conversations: IL-17 Inhibitors Hold Psoriasis Inflammation in Check – Webcast
  • The interleukin (IL)-23/IL-17 pathway is the predominant inflammatory, cytokine pathway involved in the pathogenesis of psoriasis. IL-17 isoforms, including IL-17A, IL-17F, and others, promote the proinflammatory activities and cytokines that result in keratinocyte proliferation. Elucidation of this pathway ... more >>
  • Psoriasis — Clinical Conversations: IL-17 Inhibitors Hold Psoriasis Inflammation in Check – Webcast
  • Clinicians caring for patients with psoriasis have multiple objectives during office visits. They assess the current severity of the psoriatic disease and also the response to current therapy. They evaluate the patient for extracutaneous manifestations of disease, particularly psoriatic arthritis, and monitor ... more >>
  • Leukemia — Case Study: Management of Relapsed/Refractory Chronic Myeloid Leukemia – @Point of Care Chapter
  • Chronic myeloid leukemia (CML) usually affects adults older than 65 years. With effective treatment, most patients achieve a life expectancy comparable to the general population. The first-line treatment of CML is a tyrosine kinase inhibitor (TKI), which most patients tolerate well. However, some patients ... more >>
  • Multiple Sclerosis — ECTRIMS: EVOLVE-MS-2 Reveals Fewer GI Events with Diroximel Fumarate – BreakingMED
  • Flushing and gastrointestinal distress are common side effects of oral fumarates used to treat multiple sclerosis, but the frequency of these events was found to be lower with diroximel fumarate than dimethyl fumarate in new data from the EVOLVE-MS-2 study.
    A. Brixey, MD
  • Multiple Sclerosis — ECTRIMS: Cortical Lesions at MS Diagnosis Predict Secondary Progressive Disease – BreakingMED
  • The presence of cortical lesions at diagnosis in patients with multiple sclerosis proved to be strongly predictive of conversion to secondary progressive MS (SPMS) and disability in a study of patients followed for almost two decades. Having more than three cortical lesions identified by MRI at diagnosis was ... more >>
    A. Brixey, MD
  • Multiple Sclerosis — ECTRIMS: 6-Month Natalizumab Dosing Schedule Efficacious, Study Finds – BreakingMED
  • Infusions of the disease-modifying therapy natalizumab—given every 6 weeks instead of the approved 4-week dosing schedule—proved to be efficacious in controlling multiple sclerosis (MS) disease activity, according to newly released data from the extended dosing NOVA study.
    K. Rodowicz, DO
  • Multiple Sclerosis — Some MS Drugs Attenuate Covid-19 Vaccine Response – BreakingMED
  • Some disease-modifying treatments (DMTs) used in multiple sclerosis (MS) may attenuate patients’ immune response to SARS-CoV-2 vaccination. The American Academy of Neurology (AAN) and other groups have called for vaccination for patients with neuromuscular disease and MS, regardless of immunosuppressive ... more >>
    V. Abramson, MD
  • Multiple Sclerosis — ECTRIMS: Reduced Covid-19 Response Seen in MS Patients on Some DMTs, Not Others – BreakingMED
  • Among multiple sclerosis patients on disease-modifying therapies, treatment with sphingosine-1-phosphate receptor modulators (S1P) and anti-CD20 monoclonal antibody therapies were associated with lower IgG immune response to vaccination against Covid-19 compared to treatment with other DMTs, researchers ... more >>
    A. Brixey, MD
  • Leukemia — CAPTIVATE Results Cement Potential of MRD-Guided Ibrutinib+Venetoclax for CLL – BreakingMED
  • In patients with chronic lymphocytic leukemia (CLL) and confirmed undetectable minimal residual disease (confirmed uMRD), treatment with first-line ibrutinib plus venetoclax—a once-daily, all-oral, chemotherapy-free regimen—effected a 1-year disease-free survival rate of 95%, according to results of the ... more >>
    V. Abramson, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Bipolar Disorder @Point of Care
  • Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... more >>
    M. Thase, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Atopic Dermatitis @Point of Care
  • Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... more >>
    L. Eichenfield, M.D.
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Psoriasis — Clinical Conversations: IL-17 Inhibitors Hold Psoriasis Inflammation in Check – Webcast
  • The interleukin (IL)-23/IL-17 pathway is the predominant inflammatory, cytokine pathway involved in the pathogenesis of psoriasis. IL-17 isoforms, including IL-17A, IL-17F, and others, promote the proinflammatory activities and cytokines that result in keratinocyte proliferation. Elucidation of this pathway ... more >>
  • Psoriasis — Clinical Conversations: IL-17 Inhibitors Hold Psoriasis Inflammation in Check – Webcast
  • Clinicians caring for patients with psoriasis have multiple objectives during office visits. They assess the current severity of the psoriatic disease and also the response to current therapy. They evaluate the patient for extracutaneous manifestations of disease, particularly psoriatic arthritis, and monitor ... more >>
  • Leukemia — Current Management With TKIs – Webcast
  • This activity provides an overview of current treatment approaches with the use of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia. Michael Deininger, MD, PhD, discusses key efficacy and safety data for the currently available TKIs, strategies to select TKI therapy for individual patients, and ... more >>
  • Leukemia — Selection of a Tyrosine Kinase Inhibitor for Relapsed, Resistant, and Intolerant CML: Comparing Benefits and Risks – Webcast
  • This activity focuses on an overview of the clinical data supporting the use of tyrosine kinase inhibitors (TKIs) for the treatment of relapsed, resistant, and intolerant chronic myeloid leukemia. Jorge Cortes, MD, presents key efficacy and safety data for the different TKIs and discusses strategies to select ... more >>
    J. Cortes,
  • Leukemia — Noncardiovascular Adverse Events Associated With Tyrosine Kinase Inhibitors Used for CML and Their Management – Webcast
  • Adverse events are common in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, and they have the potential to impact life quality, drug adherence, and disease response. Julie Baker, DNP, MS, APRN, guides viewers through the unique toxicity profile of each tyrosine kinase ... more >>
  • Leukemia — Beyond First-Line Therapy: Consideration for Individualizing TKI Selection – Webcast
  • In this brief presentation, Nikolai Podoltsev, MD, PhD, highlights key considerations for individualizing later-line therapy for patients with chronic myeloid leukemia. Using a case study, Dr. Podoltsev explains how to determine whether a change in treatment is warranted, and he summarizes the disease and ... more >>
  • Leukemia — Cardiotoxicities of TKIs – Webcast
  • Elias Jabbour, MD, provides a punchy review of the data illustrating the differences among the tyrosine kinase inhibitors in cardiovascular adverse events, the magnitude of the risk, and changes in risk over time. After summarizing the risk:benefit trade-off, Dr. Jabbour reviews best practices for ... more >>
    E. Jabbour, MD
  • Leukemia — Patient Monitoring and When to Modify Therapy for Resistance – Webcast
  • This activity highlights strategies for developing a treatment plan for an individual diagnosed with chronic myeloid leukemia (CML). Most importantly, Michael J Mauro, MD, reviews key milestones of response to tyrosine kinase inhibitors and the importance of early molecular response in terms of long-term ... more >>
    M. Mauro, MD
  • Leukemia — Improving the Patient-Provider Connection – Webcast
  • This activity reviews the importance of adherence to tyrosine kinase inhibitors for optimal response and clinical outcomes in patients with chronic myeloid leukemia. In addition, Lisa Barbarotta, MSN, ANP-C, AOCNS, discusses strategies to optimize the patient-provider relationship with the goal of promoting ... more >>
  • ALS — Case Study: Management of a Patient Newly Diagnosed With Amyotrophic Lateral Sclerosis – Case Study
  • Treatment options for amyotrophic lateral sclerosis (ALS) have expanded in recent years with the availability of disease-modifying and symptomatic therapies that can be offered to individuals living with ALS and have the potential to improve the quality and the length of their lives. In addition, ... more >>
    R. Bedlack, Jr, MD, PhD, FAAN
  • ALS — Case Study: Management of a Patient Newly Diagnosed With Amyotrophic Lateral Sclerosis – Case Study
  • Treatment options for amyotrophic lateral sclerosis (ALS) have expanded in recent years with the availability of disease-modifying and symptomatic therapies that can be offered to individuals living with ALS and have the potential to improve the quality and the length of their lives. In addition, ... more >>
    R. Bedlack, Jr, MD, PhD, FAAN
  • Diabetes — Utilization of SGLT-2 Inhibitor Therapy for the Primary Prevention of Cardiovascular Events in a Patient With T2DM – Case Study
  • The sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a class of agents that lower glucose but have also recently been shown to have effects on reducing cardiovascular and renal morbidities. This case illustrates the clinical scenario of a patient with type 2 diabetes mellitus (T2DM) who was initiated on ... more >>
  • Cardiology Care Considerations — Treatment of an Elderly Patient at High Risk for Stroke During the Covid-19 Pandemic – Case Study
  • The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients ... more >>
    P. Dorian, MD
  • COPD — Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD – Case Study
  • Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... more >>
  • Heart Failure — Patient With Worsening HFrEF and Prediabetes – Case Study
  • Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy, and include use of agents that modulate all pathways known to affect HF outcomes. This includes evidence-based beta blockers and agents that inhibit the renin-angiotensin-aldosterone ... more >>
    J. Butler, MD, MPH, MBA
  • Heart Failure — Patient With Worsening HFrEF and Multiple Hospitalizations – Case Study
  • Patients with heart failure (HF) with reduced ejection fraction should be managed using guideline-directed medical therapy, which includes agents that block the renin-angiotensin system, such as angiotensin converting enzymes inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin ... more >>
    J. Udelson, MD
  • Ovarian Cancer — Combination First-Line Maintenance Therapy in Ovarian Cancer – Case Study
  • The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as ... more >>
    L. Randall, MD, MAS
  • Asthma — Case Study: Investigational Single-Inhaler Triple Therapy for Uncontrolled Asthma – Case Study
  • Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics ... more >>
    W. Soong, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information